Application of benzisoselenazole derivative combined with platinum drug to preparation of tumor treatment drugs and postoperative tumor recurrence drugs

A technology of benzisoselenazole and derivatives, applied in the field of tumor treatment, can solve the problems of difficulty in re-treatment of recurrent tumors, increased difficulty in treatment, difficulty in cancer and the like

Pending Publication Date: 2020-03-03
SHANGHAI YUANXI MEDICINE CORP
View PDF1 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] Generally speaking, recurrent cancer is more difficult than initial cancer treatment. The main reasons are: 1. Local treatments such as initial surgery or radiotherapy have eliminated cancer cells as much as possible, but there may still be some extremely small cancer cell groups, Migrated out of the scope of surgery and radiotherapy very early
These cancer cell populations are often very aggressive (rapid growth and rapid spread), that is, recurrent tumors are composed of subgroups with a very high degree of malignancy. For tumors with further increased malignancy, t

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of benzisoselenazole derivative combined with platinum drug to preparation of tumor treatment drugs and postoperative tumor recurrence drugs
  • Application of benzisoselenazole derivative combined with platinum drug to preparation of tumor treatment drugs and postoperative tumor recurrence drugs
  • Application of benzisoselenazole derivative combined with platinum drug to preparation of tumor treatment drugs and postoperative tumor recurrence drugs

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0130] BS and CDDP were administered simultaneously in a molar ratio of 1:1.

Embodiment 2

[0132] BS and CDDP were administered simultaneously in a molar ratio of 2:1.

Embodiment 3B

[0133] Example 3 In vitro experimental research on the combined application of BS and CDDP to inhibit tumor cell proliferation

[0134] 3.1 The inhibitory effect of BS, CDDP single drug and the combination of the two on the proliferation of tumor cells

[0135] Bel-7402 cells, LoVo cells, HeLa cells and A549 cells were incubated with BS single drug, CDDP single drug, combined drug of Example 1, and combined drug of Example 2 for 24h, 48h, and 72h respectively, and the cell proliferation inhibition rate was determined by SRB method .

[0136] IC of BS, CDDP single drug and the combination of the two in the treatment of cancer cells 50 (half inhibitory concentration) and MI (maximum inhibitory rate) values ​​are shown in Table 1. BS, CDDP single drug and combined drug groups inhibited the growth of cancer cells in a time-dependent manner.

[0137] Table 1. IC of BS, CDDP single drug and combination of the two in inhibiting cancer cell proliferation 50 value and MI value

[...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention belongs to the technical field of tumor treatment, and discloses application of a benzisoselenazole derivative combined with a platinum drug to the preparation of tumor treatment drugs and postoperative tumor recurrence drugs. The benziselenazole derivative has a structure as shown in the formula A, the platinum-based anticancer drug is selected from at least one of cisplatin, carboplatin, oxaliplatin, nedaplatin, and the like. The molar ratio of the benziselenazole derivative to the platinum-based anticancer drug is (1-99): (1-99). With the combination of the benzisoselenazole derivative and the platinum drug, the dosage of platinum-based anticancer drug with high toxicity can be effectively reduced and the safety of anticancer drugs can be improved; and Bel-7402 cell apoptosis can be induced by reducing Bcl-2/Bax protein expression ratio, and the expression of TrxR in tumor tissues can be synergistically inhibited, the proliferation rate of tumor cells after operation can be significantly reduced, and the growth inhibition rate of tumor cells after operation can be improved.

Description

technical field [0001] The invention belongs to the technical field of tumor treatment, and specifically relates to the application of a benzisoselenazole derivative combined with a platinum drug in the preparation of a drug for treating tumor and a drug for postoperative tumor recurrence. Background technique [0002] Tumors, especially malignant tumors, are global killers of human health and one of the main causes of high mortality from diseases. Clinical treatment methods for tumors mainly include surgery, radiotherapy and chemotherapy. However, even after the above treatments, the probability of rapid tumor proliferation and recurrence remains high, making anticancer treatment one of the most challenging problems worldwide. [0003] The survival of cancer cells in the body caused by incomplete cancer treatment is the main reason for the recurrence of cancer cells. The main treatment methods for cancer are surgery, radiotherapy, and chemotherapy. Surgery is a mechanical...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/41A61K33/243A61P35/00A61P35/02
CPCA61K31/41A61K33/24A61P35/00A61P35/02A61K2300/00
Inventor 曾慧慧尹汉维
Owner SHANGHAI YUANXI MEDICINE CORP
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products